Guide Use of Tocilizumab for COVID-19 Based on New Data
March 2021
You'll hear renewed interest in tocilizumab for COVID-19...based on new data suggesting it reduces mortality in some patients.
IL-6 inhibitors, such as tocilizumab (Actemra), sparked early interest in COVID-19 to block cytokines and reduce inflammation.
But trials haven't consistently demonstrated a benefit.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote